850411-07-3

Basic information

• Product Name: [3-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PHENOXY]-ACETIC ACID ETHYL ESTER
• Synonyms: [3-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PHENOXY]-ACETIC ACID ETHYL ESTER;3-(ETHOXYCARBONYL)METHOXYPHENYLBORONIC ACID, PINACOL ESTER;3-(2-Ethoxy-2-oxoethoxy)phenylboronic acid,pinacol ester;ethyl 2-[3-(tetraMethyl-1,3,2-dioxaborolan-2- yl)phenoxy]acetate;Ethyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetate
• CAS NO: 850411-07-3
• Molecular Formula: C₁₆H₂₃BO₅
• Molecular Weight: 306.16
• Product Categories: Heterocyclic Compounds
• Mol File: 850411-07-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 405.1 °C at 760 mmHg
• Flash Point: 198.8 °C
• Appearance: /
• Density: 1.09 g/cm³
• Vapor Pressure: 8.97E-07mmHg at 25°C
• Refractive Index: 1.495
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: [3-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PHENOXY]-ACETIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: [3-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PHENOXY]-ACETIC ACID ETHYL ESTER(850411-07-3)
• EPA Substance Registry System: [3-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PHENOXY]-ACETIC ACID ETHYL ESTER(850411-07-3)

Safety Data

• Hazardous Substances Data: 850411-07-3(Hazardous Substances Data)

Usage

Uses

3-(2-Ethoxy-2-oxoethoxy)phenylboronic acid, pinacol ester

InChI:InChI=1/C16H23BO5/c1-6-19-14(18)11-20-13-9-7-8-12(10-13)17-21-15(2,3)16(4,5)22-17/h7-10H,6,11H2,1-5H3

Upstream product

• 105-36-2 ethyl bromoacetate 
• 214360-76-6 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 
• 73183-34-3 bis(pinacol)diborane 
• 591-20-8 3-Bromophenol 

Downstream Products

• 1310361-44-4 C₃₁H₂₆N₂O₃ 
• 1034020-66-0 ethyl {3-[6-(hydroxymethyl)pyridin-2-yl]phenoxy}acetate 

Relevant articles and documents

Biphenyl compound as well as preparation method and medical application thereof

The invention discloses a biphenyl compound as well as a preparation method and medical application thereof, the structure of the biphenyl compound is shown as a formula (I) or a formula (II), and thebiphenyl compound or pharmaceutically acceptable salt, tautomer, meso-isomer, raceme, stereoisomer, metabolite, metabolite precursor, prodrug or solvate thereof is a PD-L1 inhibitor. The compound hasa remarkable inhibiting effect on the interaction of PD-1 and PD-L1 protein, so that the compound can be applied to the preparation of PD-L1 inhibitors and immunomodulator drugs for preventing or treating tumors, autoimmune diseases, organ transplant rejection, infectious diseases and inflammatory diseases.